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Abstract During development, tissue repair, and tumor growth, most blood vessel networks are 
generated through angiogenesis. Vascular endothelial growth factor (VEGF) is a key regulator of 
this process and currently both VEGF and its receptors, VEGFR1, VEGFR2, and Neuropilin1 (NRP1), 
are targeted in therapeutic strategies for vascular disease and cancer. NRP1 is essential for vascular 
morphogenesis, but how NRP1 functions to guide vascular development has not been completely 
elucidated. In this study, we generated a mouse line harboring a point mutation in the endogenous 
Nrp1 locus that selectively abolishes VEGF-NRP1 binding (Nrp1VEGF−). Nrp1VEGF− mutants survive to 
adulthood with normal vasculature revealing that NRP1 functions independent of VEGF-NRP1 
binding during developmental angiogenesis. Moreover, we found that Nrp1-deficient vessels have 
reduced VEGFR2 surface expression in vivo demonstrating that NRP1 regulates its co-receptor, 
VEGFR2. Given the resources invested in NRP1-targeted anti-angiogenesis therapies, our results 
will be integral for developing strategies to re-build vasculature in disease.
DOI: 10.7554/eLife.03720.001
Introduction
Blood vessels provide oxygen and nutrients to cells throughout the body and are essential for tissue 
homeostasis and repair as well as tumor growth. The molecular mechanisms underlying angiogenesis 
have become increasingly clear, and VEGF is an essential player in this process (Carmeliet et al., 1996, 
1999; Ferrara et al., 1996, 2003; Iruela-Arispe and Dvorak, 1997; Miquerol et al., 1999; Ruhrberg 
et al., 2002; Stalmans et al., 2002; Rossant and Hirashima, 2003; Maes et al., 2004; Coultas et al., 
2005; Olsson et al., 2006; Chung and Ferrara, 2011). VEGF operates by interacting with three receptors, 
VEGFR1, VEGFR2 (KDR/Flk1), and NRP1 (Ferrara et al., 2003; Chung and Ferrara, 2011). Although 
these three receptors are expressed in spatially and temporally overlapping patterns, they are thought 
to play different roles in VEGF signaling. The main receptor for VEGF, VEGFR2, is a receptor tyrosine 
kinase whose activity is crucial for VEGF signaling (Olsson et al., 2006). Upon binding VEGF, VEGFR2 
phosphorylates intracellular targets leading to a multitude of cellular responses including proliferation, 
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migration, and transcriptional modification via signaling pathways such as PI3K, Src, and PLCϒ (Olsson 
et al., 2006). In contrast, NRP1 is a multifaceted transmembrane receptor that not only binds VEGF 
and forms a complex with VEGFR2 but also binds a structurally and functionally unrelated family of 
traditional axon guidance cues, the secreted class 3 semaphorins (SEMA3) (He and Tessier-Lavigne, 
1997; Kolodkin et al., 1997; Soker et al., 1998). Consistent with these binding partners, Nrp1−/− mice 
are embryonically lethal with both neural and vascular defects (Kitsukawa et al., 1997; Kawasaki 
et al., 1999), indicating that NRP1 protein is instrumental for developmental angiogenesis. However, 
how NRP1 functions in conjunction with multiple ligands and receptors to guide vascular development 
remains elusive.
Previous work has started to systematically dissect NRP1 function in vivo using a combination of 
structure–function analyses and mouse genetic approaches. In particular, endothelial-specific NRP1 
knock-outs (Tie2-Cre;Nrp1fl/−) recapitulate the devastating vascular defects observed in Nrp1−/− mice—
the vascular network is poorly developed and large endothelial cell aggregates form within the brain 
(Gu et al., 2003). This result strongly demonstrates that NRP1 is a cell autonomously required in 
endothelial cells for its absolutely essential function in developmental angiogenesis. To pinpoint how 
SEMA3-NRP1 vs VEGF-NRP1 binding contributes to NRP1's critical role in vascular development, 
previous work generated a knock-in mouse line, Nrp1Sema−, in which SEMA3-NRP1 interactions were 
abolished and VEGF-NRP1 binding was maintained (Gu et al., 2003). Nrp1Sema− mice mimicked the 
neural defects observed in the Nrp1−/− but did not exhibit any vascular abnormalities. These data 
suggest that SEMA3-NRP1 binding does not mediate NRP1's important function in vascular mor-
phogenesis and instead point to the hypothesis that VEGF-NRP1 interactions may be integral for 
angiogenesis.
eLife digest Blood flows through blood vessels to carry oxygen and nutrients towards, and 
waste away from, the cells of the body. New blood vessels are formed not only during development 
but also throughout life as part of normal tissue growth and repair. However, blood vessels may also 
form as a consequence of diseases, such as cancer. For example, tumors often stimulate the growth 
of new blood vessels to ensure a good supply of blood carrying nutrients and oxygen. As such, some 
anti-cancer therapies try to stop blood vessels from developing in an attempt to slow down or 
prevent tumor growth.
New blood vessels often form by branching off from existing vessels. One molecule that 
stimulates this branching process is called vascular endothelial growth factor (or VEGF for short). 
Three ‘receptor’ proteins found on the outside of cells can bind to the VEGF molecule and then 
trigger a response inside the cell that guides the development of new blood vessels. VEGF and its 
receptor proteins—including one called NRP1—are being investigated as a possible target for 
drugs that could treat cancer and other diseases affecting blood vessels. However, the exact 
mechanisms that control the formation of new blood vessels are not fully understood, which makes 
it difficult to develop these treatments.
Now Gelfand et al. have created mice whose NRP1 receptors cannot bind VEGF. These mice 
unexpectedly survive to adulthood and develop normal blood vessels. This outcome is in contrast 
to mice that lack NRP1, which normally die as embryos and have severe defects with their nerves 
and blood vessels. Gelfand et al. instead found that mice that only lack NRP1 in the cells of their 
blood vessels had less of another receptor protein called VEGFR2 on the surface of these cells. 
This result suggests that NRP1 controls blood vessel development, not by binding to VEGF but 
by affecting how much of the VEGFR2 receptor is available to interact with VEGF.
These findings challenge the long-held view of how NRP1 functions and lead Gelfand et al. to 
suggest a new mechanism: NRP1 interacts with VEGFR2, rather than with VEGF, to control the 
formation of new blood vessels. Future work will aim to uncover how these interactions regulate the 
normal development of blood vessels, and if other molecules that bind to NRP1 are involved in this 
process. Furthermore, these findings may help to guide the on-going efforts to develop drugs that 
target NRP1 into treatments that are effective against diseases that involve problems with blood 
vessels—including diabetes, immune disorders, and cancer.
DOI: 10.7554/eLife.03720.002Developmental biology and stem cells
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Currently, the dominant view in the field asserts that VEGF-NRP1 binding enhances VEGFR2 activity 
and downstream signaling. Yet, the functional consequence of VEGF-NRP1 interactions has only been 
studied indirectly using in vitro methodology and blocking antibodies in vivo (Pan et al., 2007; Herzog 
et al., 2011). Specifically, an antibody inhibiting VEGF-NRP1 binding was found to interfere with ret-
inal vascular remodeling as well as tumor angiogenesis (Pan et al., 2007) and is currently being devel-
oped as a therapeutic strategy to block vessel outgrowth. This study suggests that VEGF-NRP1 binding 
facilitates pathological angiogenesis. However, in vivo evidence describing a role for VEGF-NRP1 
binding in vascular development is currently lacking and the precise function of NRP1 in VEGF-
mediated angiogenesis urgently needs to be addressed.
To delineate the role of VEGF-NRP1 interactions, we identified a single amino acid residue in the 
b1 domain of NRP1 that is necessary for VEGF-NRP1 binding and generated a mouse harboring this 
point mutation to abolish VEGF-NRP1 interactions in vivo (Nrp1VEGF−). Surprisingly, although VEGF-
NRP1 binding was successfully eliminated, the Nrp1VEGF− mutants survived into adulthood and did not 
display any of the severe vascular phenotypes seen in either the Nrp1−/− or the endothelial-specific 
NRP1 knock-out. Upon closer examination, NRP1-deficient blood vessels in the endothelial-specific 
NRP1 knock-out exhibited reduced VEGFR2 surface expression, a phenomenon not observed in the 
Nrp1VEGF− mutant. These results challenge the well-accepted view that NRP1 requires VEGF-NRP1 
binding to facilitate developmental angiogenesis and points to a provocative new hypothesis that the 
angiogenic role of NRP1 lies in its capacity as a VEGFR2 co-receptor. Interestingly, retinal angiogenesis 
and blood flow recovery following hindlimb ischemia were mildly perturbed in the Nrp1VEGF− mutant 
suggesting that the postnatal vascular system is uniquely sensitive to the loss of VEGF-NRP1 binding. 
Together, this work not only significantly advances our basic scientific understanding of how NRP1 
functions in VEGF-mediated angiogenesis, but also provides new insights that may facilitate the devel-
opment of more effective NRP1-targeted anti-angiogenesis therapies.
Results
Identification of an Nrp1 mutation that abolishes VEGF-NRP1 binding
We sought to elucidate the in vivo function of VEGF-NRP1 binding by generating a mouse line that 
selectively disrupts VEGF binding to NRP1. A previous structure–function analysis revealed that the b1 
domain of NRP1 is necessary and sufficient for VEGF binding (Gu et al., 2002). However, this b1 
region is also required for SEMA3-NRP1 interactions, so a series of Nrp1 variants containing smaller 
deletions in the b1 domain were engineered with site-directed mutagenesis to identify a region 
specific for VEGF-NRP1 binding (Figure 1A). Based upon previous publications, we first targeted two 
specific sites in the b1 domain: the 7-residue binding site of the Pathologische Anatomie Leiden-
Endothelium (PAL-E) monoclonal antibody which competes with VEGF for NRP1 binding (Jaalouk 
et al., 2007) and the 3-residue binding site of the VEGF analog tuftsin (Vander Kooi et al., 2007) 
(Figure 1A–B). COS-1 cells were transfected with wild-type (WT) or mutant Nrp1 constructs and assessed 
for NRP1 expression. PAL-E and tuftsin binding site mutations did not affect NRP1 protein expression at 
the cell surface as examined by non-permeabilized antibody staining (Figure 1C, Figure 1—figure 
supplement 1). Ligand binding to NRP1 was assessed using alkaline phosphatase-tagged VEGF 
(AP-VEGF) and SEMA3A (AP-SEMA3A) in conjunction with alkaline phosphatase histochemistry. All of 
the PAL-E or tuftsin binding site variants were capable of abolishing VEGF-NRP1 binding, but unfortu-
nately, also eliminated SEMA3-NRP1 binding (Figure 1C, Figure 1—figure supplement 1).
We decided to use an unbiased approach and designed our subsequent Nrp1 variants based upon 
the crystal structure of the full NRP1 b1 domain. Specifically, we identified a hydrophilic region com-
prised of several negatively charged residues that provided a promising mutagenesis site for abolish-
ing VEGF-NRP1 binding (Figure 1A). Several of these residues were mutated to amino acids of the 
opposite charge in order to preserve the hydrophilic nature of the region. As with previous Nrp1 
variants, NRP1 surface expression was unperturbed in transfected COS-1 cells (Figure 1C). One of 
these mutations (E282K) did not affect the binding of either AP-SEMA3A or AP-VEGF, while others 
(E282K and E420K) eradicated binding of both the ligands (Figure 1—figure supplement 1). However, 
the D320K mutation converting aspartic acid 320 into lysine (Nrp1D320K) successfully abolished VEGF-NRP1 
binding while conserving AP-SEMA3A binding as demonstrated through alkaline phosphatase 
histochemical staining on transfected COS-1 cells (Figure 1C, Figure 2A,C). Moreover, the Nrp1D320K 
mutation also abolished the binding of other VEGF family members including Placenta Growth Factor Developmental biology and stem cells
Gelfand et al. eLife 2014;3:e03720. DOI: 10.7554/eLife.03720  4 of 18
Research article
(PlGF) and Vascular Endothelial Growth Factor B (VEGFB) (Figure 2—figure supplement 1). In a liquid 
alkaline phosphatase activity assay, Nrp1D320K was co-expressed with PlexinA4 (Plex4A) to more accu-
rately reflect the in vivo situation in which SEMA3A signals through a holoreceptor complex of both 
NRP1 and PlexinA. AP-SEMA3A binding levels to WT NRP1 and NRP1D320K were indistinguishable 
(Figure 2D), and the dissociation constant (KD) of SEMA3A-NRP1D320K/PlexinA4 was unchanged from 
that of SEMA3A-NRP1/PlexinA4 further verifying that the SEMA3A-NRP1/PlexinA4 interaction was 
intact (Figure 2E). Finally, Western blot analysis confirmed that NRP1 protein expression levels were 
equivalent in COS-1 cells transfected with WT Nrp1 and Nrp1D320K (Figure 2B). Taken together, these 
Figure 1. Design and assessment of Nrp1 variants harboring mutations in the VEGF-binding site. (A) Schematic representation of the NRP1 b1 extracellular 
domain and crystal structure highlighting three potential mutagenesis sites: the PAL-E binding site (orange circle), tuftsin binding site (blue circle), 
and electronegative surface (red circle). (B) Sequence of the Nrp1 b1 domain indicating the deletion or mutation sites for the candidate constructs. 
(C) AP-SEMA3A (top row) or AP-VEGF (middle row) binding to COS-1 cells overexpressing the indicated constructs. Deletion of the entire PAL-E binding 
site (Nrp1PAL-EΔ7) or partial deletion of the PAL-E binding site (Nrp1PAL-EΔ6 and Nrp1PAL-E Δ5) eliminated both AP-SEMA3A and AP-VEGF binding. Likewise, 
mutations in the tuftsin binding site (S346A, E348A, T349A or S346A, E348A) abolished AP-SEMA3A binding and reduced AP-VEGF binding. Although 
mutations in the NRP1 electronegative surface (E319K, D320K) eliminated AP-VEGF binding and reduced AP-SEMA3A binding, the E319K mutation only 
slightly reduced AP-SEMA3A binding and maintained AP-VEGF binding. Antibody staining of unpermeabilized cells (lower row) demonstrated normal 
NRP1 surface expression. Scale bar: 50 μm.
DOI: 10.7554/eLife.03720.003
The following figure supplement is available for figure 1:
Figure supplement 1. Assessment of additional Nrp1 variants containing mutations in the VEGF-binding site. 
DOI: 10.7554/eLife.03720.004Developmental biology and stem cells
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data demonstrate that the Nrp1D320K mutation is sufficient to eliminate VEGF binding and maintain 
SEMA3A binding in vitro.
Generation and validation of the Nrp1VEGF− mouse line
A gene replacement strategy was implemented to generate a mouse line harboring the Nrp1D320K 
mutation in the endogenous Nrp1 locus, delineated as Nrp1VEGF−. Specifically, two base pair mutations 
were introduced into exon 6 of the mouse Nrp1 gene to produce the D320K mutation in the endoge-
nous Asp320 location (Figure 3A). After recombineering, embryonic stem cells were screened via PCR 
and sequenced to confirm that the D320K mutation was appropriately introduced into the Nrp1 locus 
(Figure 3—figure supplement 1A–C). Once Nrp1VEGF− mice were obtained, the presence of the D320K 
mutation was verified by sequencing (Figure 3—figure supplement 1D). Importantly, the Nrp1VEGF− 
mutants expressed normal levels of NRP1 protein as assessed by Western blot on embryonic day 14.5 
(E14.5) lung and adult heart, brain, lung and kidney (Figure 3C, Figure 3—figure supplement 2D). 
AP-VEGF and AP-SEMA3A binding was examined at E12.5 in the dorsal root entry zone (DREZ), 
Figure 2. The Nrp1D320K mutation selectively eliminates VEGF-NRP1 binding in vitro. (A) AP-VEGF binding in COS-1 cells overexpressing the indicated 
Nrp1 construct. WT NRP1 bound AP-VEGF strongly, while AP-VEGF binding to NRP1D320K was abolished. Scale bar: 100 μm (B) Western blot shows that 
equivalent levels of NRP1 protein in COS-1 cells transfected with the WT Nrp1 and Nrp1D320K. (C) Quantification of the binding assay shows that 
AP-VEGF-NRP1D320K binding was abolished even after normalization for protein content and NRP1 expression. (D) Quantification of AP-SEMA3A binding 
shows comparable AP-SEMA3A binding to WT NRP1 and NRP1D320K. (E) Measurement of the dissociation constant (KD) of AP-SEMA3A demonstrates that 
AP-SEMA3A bound to the NRP1D320K/PlexA4 complex with the same affinity as the NRP1/PlexA4 complex.
DOI: 10.7554/eLife.03720.005
The following figure supplement is available for figure 2:
Figure supplement 1. VEGFA, VEGFB, and PLFG binding to NRP1 was abolished in the Nrp1D320K mutant. 
DOI: 10.7554/eLife.03720.006Developmental biology and stem cells
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where NRP1-expressing axons from the dorsal root ganglion enter the spinal cord. Both AP-VEGF 
and AP-SEMA3A bound to the DREZ in control animals (Figure 3B) while AP-VEGF binding to the 
DREZ was abolished in the Nrp1VEGF− mutant (Figure 3B), confirming that this mutation eliminated 
VEGF-NRP1 binding in vivo. Moreover, NRP1 immunostaining and AP-SEMA3A binding to the 
DREZ appeared similar between Nrp1VEGF− and control littermates (Figure 3B). Finally, the Nrp1VEGF− 
mutants failed to display the perinatal lethality or cardiac defect observed in the Nrp1Sema− mutants 
(Gu et al., 2003), further confirming functional SEMA3-NRP1 binding in Nrp1VEGF− mice (Figure 3— 
figure supplement 1).
VEGF-NRP1 binding is not required for developmental angiogenesis
Despite the embryonic lethality previously described in Nrp1−/− and Tie2-Cre,Nrp1fl/− animals, Nrp1VEGF− 
mice were born at expected Mendelian ratios and maintained their vitality into adulthood (p > 0.05 for 
observed vs expected, Figure 3—figure supplement 2E). The Nrp1VEGF− mutants exhibited normal 
gross morphology throughout embryonic and postnatal stages (Figure 3D,E) and failed to develop the 
cardiac defects previously observed in the Nrp1−/−, Tie2-Cre;Nrp1fl/−, and Nrp1Sema− mutants (Figure 3—
figure supplement 2A). Moreover, Nrp1VEGF− animals displayed normal body weight (Figure 3F), 
organ growth (Figure 3—figure supplement 2B,C), and fertility.
Figure 3. Nrp1VEGF- mice selectively abolish VEGF-NRP1 binding in vivo. (A) Targeting vector design for the 
generation of Nrp1VEGF− mice. The WT genomic region contained residue D320 in exon 6 of Nrp1. The targeting 
vector (TV) introduced the D320K mutation along with an Frt-flanked NeoR cassette to form the targeted allele 
(TA). After FlpE-mediated excision of the NeoR cassette, the final targeted allele (FTA) had the D320K mutation as 
well as one remaining Frt site. (B) Section binding assays demonstrated that AP-VEGF binding to the dorsal root 
entry zone (DREZ) was abolished in the Nrp1VEGF− mutants (arrows, left panels) while AP-SEMA3A binding to the 
DREZ appeared similar between Nrp1VEGF− and control animals (arrows, middle panels). Scale bar: 100 μm. (C) Western 
blot from E14.5 lung tissue shows that NRP1 protein level was not affected in Nrp1VEGF− animals. (D and E) Nrp1VEGF− 
mutants appear indistinguishable from controls littermates at embryonic (E14.5) and adult stages. (F) Nrp1VEGF− 
mutants exhibit normal body weight in adulthood (n = 7, males).
DOI: 10.7554/eLife.03720.007
The following figure supplements are available for figure 3:
Figure supplement 1. Screening and verification of ES cells for the generation of the Nrp1VEGF− mutant. 
DOI: 10.7554/eLife.03720.008
Figure supplement 2. The Nrp1VEGF− mutant mice exhibit normal gross morphology. 
DOI: 10.7554/eLife.03720.009Developmental biology and stem cells
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To thoroughly examine vascular integrity during development, isolectin staining was employed to 
visualize blood vessels in embryonic and perinatal brain sections and vessel ingression, morphology, and 
branching were assessed in the Nrp1VEGF− mutant. Surprisingly, Nrp1VEGF− animals did not exhibit any of 
the vascular abnormalities observed in the endothelial-specific NRP1 knock-out. As shown in Figure 4A 
and quantified in Figure 4B–C, cortical vessel ingression was nearly absent in Tie2-Cre;Nrp1fl/fl animals at 
E11.5 while ingression was unaffected in the Nrp1VEGF− mutants. In addition, Tie2-Cre;Nrp1fl/fl animals had 
abnormally large vascular aggregates distributed throughout the striatum at E14.5 while vessels were 
evenly dispersed without aggregates in both control and Nrp1VEGF− animals (Figure 4D–F). Finally, Tie2-
Cre;Nrp1fl/fl animals had a significant decrease in vessel branching in the cortex at E14.5 while Nrp1VEGF− 
animals exhibited normal vessel branching (Figure 4G–I). Moreover, unlike the endothelial-specific NRP1 
knock-out, the long term viability of the Nrp1VEGF− mutants allowed us to assess cortical vessel branching 
and coverage at P7 which was indistinguishable from control littermates (Figure 4G–I, Figure 4—figure 
supplement 1). Therefore, VEGF-NRP1 binding is not required for developmental angiogenesis.
NRP1 functions to modulate VEGFR2 levels independent of  
VEGF-NRP1 binding
The normal developmental angiogenesis observed in the Nrp1VEGF− mutants clearly demonstrates 
that VEGF-NRP1 binding is not responsible for the vascular defects observed in Nrp1−/− or endothelial-
specific NRP1 knock-outs. In this regard, NRP1 must function through an alternative mechanism to 
regulate vascular development during embryogenesis. The intracellular domain of NRP1 does not 
have any obvious enzymatic activity and is not responsible for the signal transduction mediating 
angiogenesis (Fantin et al., 2011; Lanahan et al., 2013). Therefore, two apparent alternatives remain. 
One possibility is that a yet unidentified ligand outside the VEGF or SEMA3 family binds to NRP1 
and instructs developmental angiogenesis. Alternatively, NRP1 may control vascular development by 
directly regulating its co-receptor, VEGFR2.
To test this second possibility, VEGFR2 expression was evaluated in the Tie2-Cre;Nrp1fl/− mutants 
and control littermates via Western blot on E14.5 lung tissue. This biochemical assay revealed that 
total VEGFR2 protein levels were significantly reduced in the Tie2-Cre;Nrp1fl/− mutants compared 
to their control littermates (Figure 5A–B). To determine the cell surface expression of VEGFR2 in vivo, 
we used fluorescence-activated cell sorting (FACS) to specifically quantify VEGFR2 expression at the 
cell surface of non-permeabilized endothelial cells derived from the acutely dissociated lungs of Tie2-
Cre;Nrp1fl/− and control embryos. Remarkably, Tie2-Cre;Nrp1fl/− mutants displayed a significant decrease 
in the fluorescence intensity of VEGFR2 labeling as compared to control littermates (Figure 5E–F), 
suggesting that NRP1 functions to regulate VEGFR2 surface expression in endothelial cells. In contrast, 
both Western blot and FACS analysis determined that VEGFR2 protein levels were unperturbed in 
Nrp1VEGF− animals (Figure 5C–D,G–F). In addition, co-immunoprecipitation on P7 lung tissue revealed 
that NRP1 and VEGFR2 are physically associated in both control and Nrp1VEGF− animals (Figure 5—figure 
supplement 1B), validating that NRP1-VEGFR2 receptor complex formation does not require VEGF-
NRP1 binding in vivo. This result mimics our co-immunoprecipitation experiments on HEK293T cells 
transfected with either WT Nrp1 or Nrp1D320K constructs (Figure 5—figure supplement 1A). Together, 
these findings indicate that NRP1 plays a role in regulating the cell surface expression of VEGFR2 in 
endothelial cells and that VEGF-NRP1 binding is not necessary for this function in vivo (Figure 5G).
To examine VEGF signaling in the Tie2-Cre;Nrp1fl/− and Nrp1VEGF− mutants, VEGFR2 phosphoryla-
tion was examined via Western blot on embryonic lung tissue isolated at E14.5. Specifically, Tie2-
Cre;Nrp1fl/− mutants had a severe reduction in VEGFR2 phosphorylation at the tyrosine residue 1175 
(Y1175) upon VEGF treatment (Figure 5—figure supplement 2A,B). Interestingly, Nrp1VEGF− mutants 
also exhibited a mild reduction in VEGFR2 phosphorylation while total VEGFR2 protein levels were 
well maintained (Figure 5—figure supplement 2C,D). Although the level of pVEGFR2 in the Nrp1VEGF− 
mutant was sufficiently high to support vascular development during embryogenesis, the modest 
reduction in pVEGFR2 may manifest in issues with angiogenesis, vascular maintenance, and regenera-
tion in the postnatal animal.
VEGF-NRP1 binding is required for postnatal angiogenesis
To directly test the role for VEGF-NRP1 binding in postnatal angiogenesis, whole-mount staining 
was performed with isolectin and an antibody against α-smooth muscle actin (α-SMA) to visualize the 
retinal blood vessels and arteries, respectively. At P9, the Nrp1VEGF− mutants exhibited a reduction in Developmental biology and stem cells
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Figure 4. VEGF-NRP1 binding is not required for developmental angiogenesis. (A) Vessel staining with isolectin 
(green) revealed that Tie2-Cre;Nrp1fl/fl mutants had delayed vessel ingression into the cerebral cortex at E11.5 while  
the Nrp1VEGF− mutants exhibited normal ingression. DAPI was used to stain the nuclei (blue). (B and C) Quantification  
of cortical vessel ingression shown in A, n = 3. (D) Tie2-Cre;Nrp1fl/fl mutants exhibited large vessel clumps  
in the brain (particularly in the striatum) at E14.5, a phenotype not observed in the Nrp1VEGF− mutants.  
(E and F) Quantification of vessel size in E14.5 striatum shown in D, n = 3. (G) Tie2-Cre;Nrp1fl/fl mutants had  
reduced vessel branching in the cerebral cortex while the Nrp1VEGF− mutants displayed normal vessel branching  
at E14.5. (H and I) Quantification of vessel branching in E14.5 cortex shown in G, n = 4. Scale bar: 200 μm.
DOI: 10.7554/eLife.03720.010
The following figure supplement is available for figure 4:
Figure supplement 1. The Nrp1VEGF− mutant mice display normal vessel branching and coverage at postnatal stages. 
DOI: 10.7554/eLife.03720.011Developmental biology and stem cells
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Figure 5. NRP1 regulates VEGFR2 expression at the cell surface independent of VEGF-NRP1 binding. (A) Western 
blot from E14.5 lung tissue treated with 50 ng/ml VEGF for 15 min revealed that VEGFR2 was reduced in Tie2-CreNrp1fl/− 
mutants while VE-cadherin expression remained at control levels. Western blot for NRP1 demonstrates that the 
Figure 5. Continued on next pageDevelopmental biology and stem cells
Gelfand et al. eLife 2014;3:e03720. DOI: 10.7554/eLife.03720  10 of 18
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the vascular extension and artery number but did not have any abnormalities in vessel coverage as 
compared with control littermates (Figure 6A). In the adult, the vascular extension and vessel coverage   
in the retina were indistinguishable from controls (Figure 6B) indicating that the Nrp1VEGF− mutants 
experience a delay in the formation of the primary vascular plexus. However, the number of retinal 
arteries remained lower in Nrp1VEGF− adults. These results demonstrate that VEGF-NRP1 interactions 
are required to some degree for postnatal angiogenesis and artery differentiation in the retina.
In addition, Nrp1VEGF− animals were also assessed for injury-induced arteriogenesis following   
femoral artery ligation. In this assay, the femoral artery was surgically severed in both Nrp1VEGF− and 
control mice, and blood flow recovery was monitored via deep penetrating laser Doppler imaging. 
Femoral artery ligation produced a comparable level of hindlimb ischemia in the Nrp1VEGF− mutants 
and controls (Figure 6—figure supplement 1). However, the Nrp1VEGF− mutants exhibited a significant 
delay in hindlimb re-perfusion. Building upon these results, future work will utilize the Nrp1VEGF− knock-in 
line to determine if VEGF-NRP1 signaling functions in pathological or physiological angiogenesis in 
the adult.
Discussion
In this study, we identified a single amino acid within the extracellular b1 domain of NRP1 that is 
required for VEGF-NRP1 binding, but non-essential for SEMA3-NRP1 interactions. A point mutation in 
this D320 residue was incorporated into the endogenous Nrp1 locus to generate the Nrp1VEGF− mutant, 
a novel mouse line that selectively abolishes VEGF-NRP1 binding in vivo. Recently a cDNA knock-in 
NRP1 mutant, Nrp1Y297A/Y297A, was also developed to examine the role of VEGF-NRP1 binding (Fantin 
et al., 2014). However, mice generated with genetically modified cDNA notoriously lack the essential 
intronic regions that regulate the temporal and spatial expression of the gene. Consequently, the 
aberrant and severe down-regulation of NRP1 protein expression in the Nrp1Y297A/Y297A hypomorph 
prevents any definitive conclusions from being garnered about the biological cause of phenotypes 
present in this mouse. In this regard, abnormalities in the Nrp1Y297A/Y297A hypomorph could originate 
from two potential sources: the severe reduction in NRP1 levels or the abolishment of VEGF-NRP1 
binding. Unlike the Nrp1Y297A/Y297A line, our Nrp1VEGF− mutant contains a two base pair replacement in 
the endogenous Nrp1 locus and preserves the genetic structure of the Nrp1 gene. Consequently, 
Nrp1VEGF− mice maintain appropriate levels of NRP1 protein expression and allow the first unobscured 
in vivo assessment of VEGF-NRP1 binding in developmental angiogenesis. Our Nrp1VEGF− line provides 
a powerful new genetic tool for selectively interrogating the function of VEGF-NRP1 binding in broad 
areas of basic research and translational study.
Remarkably, our Nrp1VEGF− mutant did not recapitulate the early embryonic lethality or develop-
mental angiogenesis phenotypes of the Nrp1−/− and endothelial-specific NRP1 knock-out (Figure 4). 
Tie2-Cre allele successfully knocked down NRP1 expression. (B) Quantification of VEGFR2 expression shown in A,  
n = 4. (C) Western blot from E14.5 lung tissue treated with 50 ng/ml VEGF for 15 min demonstrates that VEGFR2, 
NRP1, and VE-cadherin expression were unperturbed in the Nrp1VEGF− mutants. (D) Quantification of VEGFR2 
expression shown in C, n = 5. (E) FACS analysis plots illustrate a reduction in VEGFR2 surface expression in 
endothelial cells isolated from Tie2-Cre;Nrp1fl/− mice. (F) Quantification of the VEGFR2 fluorescence intensity 
from the FACS analysis shown in E, n = 5. (G) FACS analysis plots demonstrate that VEGFR2 surface expression 
in endothelial cells isolated from Nrp1VEGF− mice remained at control levels. (H) Quantification of the VEGFR2 
fluorescence intensity from the FACS analysis shown in G, n ≥ 7. (I) Schematic of VEGFR2 and NRP1 at the  
cell surface illustrates VEGF ligand binding to both VEGFR2 and NRP1. In the Nrp1VEGF− mutants, VEGF-NRP1 
binding is abolished, VEGFR2 has normal cell surface localization, and vascular development proceeds 
appropriately. However, in Nrp1−/− mutants, VEGFR2 cell surface localization is reduced and vascular  
development is impaired.
DOI: 10.7554/eLife.03720.012
The following figure supplements are available for figure 5:
Figure supplement 1. VEGF-NRP1 binding is not required for NRP1-VEGFR2 complex formation in vitro and in vivo. 
DOI: 10.7554/eLife.03720.013
Figure supplement 2. VEGF-induced VEGFR2 phosphorylation is reduced in both the Nrp1VEGF− and 
Tie2-Cre;Nrp1fl/− mutants. 
DOI: 10.7554/eLife.03720.014
Figure 5. ContinuedDevelopmental biology and stem cells
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Moreover, the Nrp1VEGF− mutant did not exhibit any of the cardiac failure, perinatal lethality, or growth 
defects observed in the Nrp1Y297A/Y297A hypomorph indicating that these phenotypes are attributed 
to the severe reduction in NRP1 protein in Nrp1Y297A/Y297A mutants rather than the lack of VEGF-NRP1 
binding. However, the Nrp1VEGF− mutant did exhibit a delay in vascular extension and a reduction in 
the number of arteries in the postnatal retina. This retinal phenotype is significantly less severe than 
those observed in the Nrp1Y297A/Y297A hypomorph (Fantin et al., 2014) or in animals treated with anti-
bodies inhibiting VEGF-NRP1 binding (Pan et al., 2007). Together, these results reveal that the 
retina relies on both VEGF-NRP1 dependent and independent mechanisms to establish the retinal 
vasculature.
Figure 6. Retinal angiogenesis is perturbed in the Nrp1VEGF− mutant. (A) Isolectin and α-SMA staining on P9 
retinal flat-mounts revealed a significant reduction in vascular extension and artery number in Nrp1VEGF− 
mutants. However, vessel coverage in the retina was unperturbed in the Nrp1VEGF− mutants, n = 6. (B) In the 
adult, isolectin and α-SMA staining showed that the number of retinal arteries remained lower in the Nrp1VEGF− 
mutants than littermate controls while vascular extension and vessel coverage in the retina were normal, n = 4. 
Scale bar: 200 μm.
DOI: 10.7554/eLife.03720.015
The following figure supplement is available for figure 6:
Figure supplement 1. The Nrp1VEGF− mutants have delayed blood flow recovery following femoral artery ligation. 
DOI: 10.7554/eLife.03720.016Developmental biology and stem cells
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Our surprising results challenge the well-accepted view that NRP1 depends on VEGF-NRP1 
binding to facilitate angiogenesis and points to a provocative new hypothesis that NRP1 functions 
independently of VEGF-NRP1 binding perhaps via its interaction with an unidentified ligand or in its 
capacity as a co-receptor for VEGFR2. Our study demonstrates that the NRP1-deficient endothelial 
cells have reduced VEGFR2 expression at the cell surface, a phenomenon that was not observed in the 
Nrp1VEGF− mutants. This result provides the first in vivo evidence that NRP1 controls VEGFR2 levels at 
the cell membrane and offers the first in vivo phenotypic characterization linking NRP1 regulated 
VEGFR2 surface expression to vascular development.
Consistent with our in vivo observations, several lines of in vitro work using multiple cell culture 
systems demonstrate that NRP1 is essential for the proper presentation, recycling, and degradation of 
VEGFR2 (Shintani et al., 2006; Holmes and Zachary, 2008; Ballmer-Hofer et al., 2011; Hamerlik 
et al., 2012). The loss of function and gain of function studies in human umbilical vein endothelial cells 
(HUVECs) found that VEGFR2 protein levels were decreased in the absence of NRP1 while Vegfr2 
mRNA levels were unaffected by Nrp1 siRNA (Shintani et al., 2006; Holmes and Zachary, 2008). 
Similarly, Hamerlik et al. (2012) examined human glioblastoma multiforme cells and found that shRNA 
mediated knock-down of NRP1 resulted in dramatically decreased VEGFR2 protein levels accompa-
nied by a lower surface presentation of VEGFR2 and a decrease in cell viability. Moreover, cell surface 
protein biotinylation and immunofluorescence staining with confocal microscopy confirmed the co-
localization of VEGFR2-NRP1 with the early/recycling endosome. Finally, Ballmer-Hofer et al., (2011) 
used stably transfected porcine aortic endothelial cell (PAEC) lines in conjunction with immunostaining 
to visually follow VEGFR2 trafficking in the presence and absence of NRP1. Their experiments revealed 
that upon VEGF stimulation, VEGFR2 is internalized in Rab7 vesicles for degradation. However, in the 
presence of NRP1, VEGFR2 is stabilized in Rab11 vesicles and recycled back to the cell surface. In 
conjunction with our in vivo results, these data demonstrate that NRP1 guides vascular development 
through its capacity as a VEGFR2 co-receptor rather binding to VEGF. In this manner, NRP1 regulates 
angiogenesis by controlling the amount of VEGFR2 expression at the cell surface and consequently 
the level of VEGFR2-VEGF signaling.
The modulation of co-receptors may function as a general mechanism for regulating cell signaling 
and behavior. A prior in vitro study identified a similar relationship between the membrane protein, 
neural cell adhesion molecule (NCAM) and fibroblast growth factor receptor-1 (FGFR1) (Francavilla 
et al., 2009). This previous work discovered that NCAM induced sustained FGFR1 activation by 
controlling the intracellular trafficking of the FGFR1 receptor. Specifically, NCAM was capable of re-
targeting internalized FGFR1 from the lysosomal degradation pathway to Rab11-postive recycling 
vesicles and increased FGFR1 expression at the cell surface. In this regard, the co-receptor interac-
tion between NRP1 and VEGFR2 may be representative of a more universal phenomenon in which 
membrane proteins function to regulate the cell surface expression and subsequent downstream 
signaling of receptors.
Ultimately, our findings mark a pivotal step toward understanding the role of NRP1 in developmen-
tal angiogenesis and indicate that NRP1-VEGFR2 interactions rather than VEGF-NRP1 binding under-
lie NRP1's critical function in VEGF-mediated vascular development. Given the substantial resources 
invested in NRP1-targeted anti-angiogenesis therapies for vascular disease and cancer, the informa-
tion gleaned from this study will be invaluable in identifying the cellular and molecular mechanisms 
underlying angiogenesis and ultimately using this information to instruct the development of new 
therapeutic approaches.
Materials and methods
Site-directed mutagenesis and targeting vector construction
Rat Neuropilin1 cDNA was re-cloned from pMT21 into pCS2+ using the original EcoRI and XhoI sites 
present in both vectors. Mutations were made using PCR, and the mutated fragment was subcloned 
back into pCS2-Nrp1 using endogenous restriction sites. The targeting vector (TV) was constructed 
using a combination of traditional cloning and recombineering along with point mutagenesis. Genomic 
DNA was obtained from the 129S7-AB2.2 BAC library, clone #bMQ-373E22. The short (3′) arm (1.3 kb) 
was cloned into the HpaI and EcoRI sites of 4600C-loxP. Two short homology arms (900 bp, total) were 
created and cloned into the XhoI and NotI sites of 4600C-loxP, with the two arms joined by a SalI site. 
The homology arms were ligated in a triple ligation to 4600C-loxP as well as to each other. The vector Developmental biology and stem cells
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was then linearized with SalI and electroporated into modified electrocompetent DH10B cells containing 
the previously mentioned BAC in order to facilitate homologous recombination to insert the remainder of 
the long arm. Recombineering was performed as described by the NCI-Frederick. After a full-length 
TV was made, the D320K mutation was introduced. The final TV was linerarized and electroporated 
into ES cells. All primer sequences used for the targeting vector construction are provided in 
Supplementary file 1.
Alkaline-phosphatase-tagged ligand production
HEK293T cells were transfected with AP-SEMA3A, AP-VEGF A, AP-VEGF B, or AP-PlGF expression 
constructs using a calcium phosphate transfection method. Media was changed after 6 hr. Cells were 
cultured for an additional 48 hr in DMEM + 10% FBS. After 48 hr the media were collected, filtered to 
remove the cell debris, and AP activity was measured. The ligands were frozen at −80°C until use.
Binding of AP-tagged protein to cells and unpermeabilized  
antibody staining
COS-1 cells were grown in DMEM + 10% fetal bovine serum (FBS) + 1% Penicillin-Streptomycin. 
Cells were transfected with the indicated expression vectors using Lipofectamine-2000 (Invitrogen, 
Carlsbad, CA) in 6-well plates. 24 hr later, transfected cells were split into 24-well plates for parallel 
AP-binding and antibody staining. 24 hr after splitting, binding was performed using AP-tagged 
ligands (AP-VEGF A, AP-SEMA3A, AP-VEGF B, AP-PlGF). The binding protocol was as follows: cells 
were washed 1× with HBHA (1× HBSS, 0.5 mg/ml BSA, 0.5% sodium azide, and 20 mM HEPES [pH 7]), 
then incubated for 75 min with 0.3 ml of 2 nM ligand. Cells were then washed 7× with HBHA on a 
rotating platform and 110 µl of cell lysis buffer (1% Triton X-100 and 10 mM Tris–HCl [pH 8]) was added 
to each well. Cells and buffer were scraped into Eppendorf tubes, then vortexed for 5 min to fully lyse 
them. The lysates were then spun down for 5 min, and the supernatant was heat inactivated at 65°C 
for 10 min to inactivate endogenous alkaline phosphatases. AP-activity was measured by adding 2× 
SEAP buffer (50 ml 2 M diethanolamine [pH 9.8], 50 µl 1 M MgCl2, 224 mg L-homoarginine, 50 mg 
BSA, 445 mg p-nitrophenylphosphate) and measuring optical absorbance at 405 nm every 15 s for 1 
min. Antibody staining of these cells was done as follows: non-specific binding was blocked with 5% 
Normal Goat Serum in DMEM for 30 min at 4°C. Cells were then incubated with primary antibody 
(Rabbit anti-NRP1, gift of Dr David Ginty) for 2 hr at 4°C. They were then washed 6× with cold HBHA, 
then incubated with a secondary antibody (AP-tagged anti-rabbit) for 1.5 hr at 4°C. Cells were then 
washed 3× in cold HBHA, then lysed as described above. AP-activity was measured from lysed extracts. 
Binding of AP-tagged ligands was normalized to protein content of each well and to antibody staining 
with an anti-NRP1 antibody. Each AP-binding assay was independently repeated three times.
Animal care
Nrp1VEGF−, Tie2-Cre, Nrp1fl, and Nrp1− (Gu et al., 2003) mice were maintained on a C57Bl/6 back-
ground. Nrp1VEGF− mice were genotyped with traditional PCR techniques. The expected WT band is 
305 bp, while the targeted allele is 350 bp due to the remaining presence of one FRT site. To sequence 
the mutation site, PCR was performed to generate a fragment around the mutation site. The primer 
sequences for genotyping and sequencing are included in Supplementary file 1. Tie2-Cre, Nrp1fl, and 
Nrp1− genotyping was performed as previously published. All animals were treated according to insti-
tutional and NIH guidelines approved by IACUC at Harvard Medical School.
AP-ligand binding to tissue sections
Embryos were dissected and frozen immediately in liquid nitrogen, then stored at −80°C until use. 
Sections were cut at 25 µm with a cryostat, then fixed for 8 min in ice-cold methanol. Sections were then 
washed 3× in PBS + 4 mM MgCl2. Non-specific binding was reduced by blocking the sections with 
DMEM + 10% FBS for 45 min. After fixation, sections were incubated with 2 nM AP-tagged ligand, 
diluted with PBS + 4 mM MgCl2, and buffered with HEPES, pH 7 for 1.5 hr at room temperature in a 
humidified chamber. The sections were washed 5× in PBS + 4 mM MgCl2, then fixed with a fixative solu-
tion (60% acetone, 1% formaldehyde, 20 mM HEPES, pH 7). Sections were washed 3× in PBS and incu-
bated in PBS at 65°C for 2 hr to heat inactive endogenous alkaline phosphatases and then incubated 
overnight in developing solution (100 mM Tris–HCl pH 9.5, 100 mM NaCl, 5 mM MgCl2) with NBT (nitro-
blue tetrazolium chloride) and BCIP (5-bromo-4-chloro-3′-indolyphosphate p-toluidine). AP-ligand 
binding was analyzed in sections from at least three animals across two different litters per genotype.Developmental biology and stem cells
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Western blotting
For immunoblotting, E14.5 lung samples were loaded on 8% polyacrylamide gels and run until the 
appropriate protein separation was achieved. Samples were electrophoretically transferred onto the 
PVDF membrane. Non-specific binding was blocked by a 1 hr incubation in 5% non-fat milk in TBST 
(Tris-buffered saline + 0.1% Tween-20). The membranes were then incubated overnight with the 
following primary antibodies, as indicated below, at 4°C: anti-NRP1 (#ab81321 Abcam, Cambridge, 
MA or gift of Dr David Ginty, see Ginty et al., 1993 for details), anti-VEGFR2 (gift of Procter and 
Gamble, see Gu et al., 2003 for details), anti-VE-cadherin (#ab33168 Abcam, Cambridge, MA), anti-
p-VEGFR2 (p1175) (#2478 Cell Signaling Technology, Danvers, MA), and anti-α-Tubulin (#T5168 Sigma-
Aldrich, Natick, MA). After incubation with primary antibodies, the membranes were washed 3× in TBST 
then incubated with the appropriate HRP-labeled secondary antibody in TBST or 5% milk in TBST for 
1 hr at room temperature. Membranes were then washed 3× with TBST then developed with regular 
or super ECL (GE Amersham, United Kingdom or Thermo Scientific, Waltham, MA). The intensity of 
individual bands was quantified using ImageJ.
Phenotypic analysis of the Nrp1VEGF− mutant
At the indicated stages, embryos were dissected, fixed with 4% paraformaldehyde, equilibrated in 
a sucrose gradient, embedded in OCT, and sectioned in the coronal plan at 12 µm with a Leica CM3050S 
cryostat. Likewise, the brains of postnatal pups (P7) were dissected, fixed, cryo-protected, and sectioned 
at 20 µm. Tissue sections were washed 3× for 5 min in 0.2% PBT (0.2% Triton X-100 in PBS), incubated 
with Isolectin GS-IB4 (#I21411 Life Technologies, Grand Island, NY) overnight at 4°C, washed 3× for 
5 min in PBS, and coverslipped with using ProLong Gold/DAPI antifade reagent (#P36935 Molecular 
Probes, Eugene, OR). Sections were imaged by fluorescence microscopy using a Nikon Eclipe 80i 
microscope equipped with a Nikon DS-2 digital camera. Quantification was performed using ImageJ. 
Vessel coverage delineates the percent of cortical pixel area covered by isolectin-positive pixels while 
vessel size quantifies the pixel area of each discrete vascular aggregate identified by isolectin staining.
VEGF lung treatment
E14.5 mouse lungs were dissected in cold PBS and minced finely using a razor blade. The tissue was 
then incubated with plain EBM (Lonza, Switzerland) or EBM containing 50 ng/ml VEGF for 15 min at 
37°C. Lysis buffer (50 mM Tris/HCl [pH 7.5], 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, and 2 mM 
DTT) containing complete proteinase inhibitors (Roche, Switzerland), PhosSTOP (Roche, Switzerland), 
and sodium orthovanadate was added to the tissue, which was then pulverized with a pestle and incu-
bated for 30 min while rotating at 4°C. Tissue was spun down and protein quantification was performed. 
The tissue was treated as described in the Western blotting section.
Co-immunoprecipitation
HEK293T cells were transfected with the indicated constructs using Lipofectamine-2000 (Invitrogen, 
Carlsbad, CA). They were then grown in DMEM + 10% fetal bovine serum + 1% Penicillin-Streptomycin and 
48 hr after transfection cells were washed and harvested in ice-cold PBS. Cells were lysed using lysis buffer 
(50 mM Tris/HCl [pH 7.5], 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, and 2 mM DTT) containing com-
plete proteinase inhibitors (Roche, Switzerland). After 30 min of rotation in the cold room and subsequent 
centrifugation, protein was quantified and 20 µg of protein was frozen down as input controls. 0.5 µg of 
anti-VEGFR2 antibody (gift of Procter and Gamble, see Gu et al., 2003 for details) was added to 500 µg of 
protein and rotated in the cold room for 1 hr. Then, 20 µl of protein A/G beads (Thermo Scientific, Waltham, 
MA) were added to the protein and rotated overnight in the cold room. Beads were washed 3× with lysis 
buffer and two times with wash buffer (lysis buffer with 300 mM NaCl). Protein was eluted by the addition 
of 2× SDS-PAGE sample buffer and boiling for 10 min. Co-immunoprecipitation was also performed on P7 
lung lysates isolated from control and Nrp1VEGF− animals treated with VEGF as described above.
FACS
Analysis of E14.5 mouse embryos were performed on single cells from dissociated lungs. In brief, microdis-
section techniques were used to isolate the lung. Lungs were then rinsed in PBS and incubated in 2 mg/ml 
collagenase and 20 μg/ml DNase I 3× for 15 min at 37°C and gently pipetted. The collagenase was 
inactivated using 5 ml of ice-cold 10% FBS/PBS, centrifuged at 1000×g for 5 min, and suspended in 
400 µl of red blood cell (RBC) lysis buffer (Sigma-Aldrich, Natick, MA). Following a 5 min incubation Developmental biology and stem cells
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at room temperature, 2 ml of ice-cold 5% FBS/PBS was added and cells were centrifuged at 1000×g 
for 5 min at 4°C. Cells were then blocked in Fc-blocking solution (#553142; BD) for 20 min on ice, 
centrifuged, incubated with the labeled conjugated primary antibodies–PE-anti-CD31 (PECAM) 
(#553373 BD Pharmingen, Franklin Lakes, NJ) and APC-anti-Flk1-1 (VEGFR2) (#560070 BD Pharmingen, 
Franklin Lakes, NJ), for 30 min on ice with agitation every 10 min. After incubation, the cells were spun 
down, the supernatant was removed, and the cell pellet was resuspend in 1:10K Sytox in PBS/5%FBS. 
Cells were analyzed on a LSR II Flow Cytometer. Cells incubated with no antibody, APC-anti-Flk1, 
or PE-anti-CD31 only served as the control population.
Phenotypic analysis of the developing retina
Whole-mount retina immunohistochemistry was performed as previously described in Kim et al., 
(2011). Briefly, eyes were extracted and fixed in 4% paraformaldehyde for 10 min at room temperature. 
Retinas were dissected in PBS and post-fixed in 4% paraformaldehyde overnight at 4°C. Retinas were 
then permeabilized in PBS, 1% BSA, and 0.5% Triton X-100 at 4°C overnight, washed 2× for 5 min 
in 1% PBT (1% Triton X-100 in PBS), and incubated in Isolectin GS-IB4 (1:200, #I21411 Life Technologies, 
Grand Island, NY) and anti-αSMA Cy3 (1:100, #C6198 Sigma-Aldrich, Natick, MA) in 1% PBT overnight 
at 4°C. Retinas were washed 3× for 5 min and flat-mounted using ProLong Gold antifade reagent 
(#P36934 Molecular Probes, Eugene, OR). Flat-mounted retinas were analyzed by fluorescence micros-
copy using a Nikon Eclipe 80i microscope equipped with a Nikon DS-2 digital camera and by confocal 
laser scanning microscopy using an Olympus FV1000 confocal microscope. Quantification was per-
formed using MetaMorph Image Analysis Software and ImageJ. At least four retinal leaves were quan-
tified per animal to determine the vascular extension ratio, both eyes were examined in each animal 
for artery number, and three representative images were quantified from each animal for vascular 
coverage (representing the total isolectin-positive pixel area per image).
Femoral artery ligation
Ketamine (80–100 mg/kg) and xylazine (5–10 mg/kg) delivered by IP injection were used to anesthe-
tize 12-week old male Nrp1VEGF− and control littermates. After anesthesia was achieved, the bilateral 
hindlimbs and lower abdomen were cleared of hair and cleaned with 10% betadine and 70% alcohol. 
An incision of 3–4 mm was made in the right inguinal area to visualize the femoral artery. Two 6–0 silk 
sutures were tied in the proximal femoral artery and the deep femoral and epigastric artery branches 
were cauterized. The femoral artery was then ligated between the two sutures. The skin was sutured 
with one 4–0 prolene sutures. Immediately before and after surgery, each animal was scanned with a 
non-invasive laser doppler imaging system (moorLD12-HR Moor Instruments, Wilmington, DE) under 
1–3% isofluorane anesthesia. Blood flow recovery in the hindlimbs was further assessed on 3, 5, and 7 
days post-surgery and quantified via Moor LDI Software.
Statistical analysis
The standard error of the mean was calculated for each experiment and error bars in the graphs rep-
resent the standard error. A paired Student's t-test was used to determine the statistical significance 
of differences between samples, and the genotype distribution was analyzed using a Chi-square test. 
Statistical analyses were performed with Prism 4 (GraphPad Software) and p values are indicated by 
* ≤ 0.05, ** ≤ 0.01, and *** ≤ 0.001.
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